CBAY
(NASDAQ)
1.40
-0.0099  (-0.71%)
Volume (24h): 2.06M Day Range: 1.38 - 1.52
Market Cap: 96.44M 52W Range: 1.21 - 13.89
Apr-02-20 08:01AM Edited Transcript of CBAY earnings conference call or presentation 12-Mar-20 8:30pm GMTThomson Reuters StreetEvents
03:12AM Edited Transcript of CBAY earnings conference call or presentation 12-Mar-20 8:30pm GMTThomson Reuters StreetEvents
Apr-01-20 11:32AM Edited Transcript of CBAY earnings conference call or presentation 12-Mar-20 8:30pm GMTThomson Reuters StreetEvents
06:12AM Edited Transcript of CBAY earnings conference call or presentation 12-Mar-20 8:30pm GMTThomson Reuters StreetEvents
Mar-20-20 02:44PM Generic Drugs Industry's Prospects Uncertain Amid CoronavirusZacks
10:30AM We're Keeping An Eye On CymaBay Therapeutics's (NASDAQ:CBAY) Cash Burn RateSimply Wall St.
Mar-13-20 09:29PM CymaBay Therapeutics Comments on Engine Capital Director NominationsBusiness Wire
Mar-12-20 08:01PM CymaBay Reports Fourth Quarter and Fiscal Year End 2019 Financial Results and Provides Corporate UpdateGlobeNewswire
06:30PM CymaBay Therapeutics, Inc. to Host Earnings CallACCESSWIRE
Mar-11-20 11:00PM HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Urges CymaBay Therapeutics (CBAY) Investors Who Have Suffered Losses to Contact its Attorneys: Firm Investigation Possible Securities FraudACCESSWIRE
Mar-10-20 04:15PM IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against CymaBay Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmACCESSWIRE
12:44PM Is the Options Market Predicting a Spike in CymaBay Therapeutics (CBAY) Stock?Zacks
Mar-09-20 11:51PM HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages CymaBay Therapeutics (CBAY) Investors Who Have Suffered Losses to Contact its Attorneys: Investigation Into Possible Securities Fraud OngoingGlobeNewswire
03:40PM SHAREHOLDER NOTICE: The Schall Law Firm Announces it is Investigating Claims Against CymaBay Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmACCESSWIRE
Mar-09-20 02:57PM ROSEN, A LEADING LAW FIRM, Announces Investigation of Securities Claims Against CymaBay Therapeutics, Inc. – CBAYGlobeNewswire
Mar-06-20 03:49PM 4 Smaller, Cash-Rich Biotech Stocks That Could Be HavensBarrons.com
12:00AM HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds CymaBay Therapeutics (CBAY) Investors Who Have Suffered Losses to Contact its Attorneys: Firm Investigating Possible Securities FraudACCESSWIRE
Mar-05-20 09:01PM CymaBay Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results on Thursday, March 12GlobeNewswire
06:30PM SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against CymaBay Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmACCESSWIRE
Mar-04-20 11:09PM CYMABAY ALERT: Bragar Eagel & Squire, P.C. Is Investigating CymaBay Therapeutics, Inc. on Behalf of Stockholders and Encourages Investors to Contact the FirmBusiness Wire
Mar-03-20 08:12PM INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against CymaBay Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmBusiness Wire
05:27PM HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages CymaBay Therapeutics (CBAY) Investors Who Have Suffered Losses to Contact its Attorneys: Firm Investigating Possible Securities FraudGlobeNewswire
Mar-03-20 04:00PM CBAY Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Investigation of CymaBay Therapeutics, Inc. and Encourages Investors to Contact the FirmPR Newswire
06:10AM IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces it is Investigating Claims Against CymaBay Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmACCESSWIRE
Mar-02-20 11:50PM CBAY Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Investigation of CymaBay Therapeutics, Inc. and Encourages Investors to Contact the FirmACCESSWIRE
11:07PM INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against CymaBay Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmBusiness Wire
Mar-02-20 09:15PM EQUITY ALERT: ROSEN, NATIONAL INVESTOR COUNSEL, Announces Investigation of Securities Claims Against CymaBay Therapeutics, Inc. – CBAYBusiness Wire
01:09PM CymaBay Therapeutics Investigated for Possible Securities Fraud by Block & LevitonGlobeNewswire
Feb-29-20 02:52AM HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages CymaBay Therapeutics (CBAY) Investors Who Have Suffered Losses to Contact its Attorneys: Firm Investigating Possible Securities FraudPR Newswire
Feb-05-20 04:52PM Steven Cohen Renews His Interest in VerastemGuruFocus.com
Jan-29-20 09:15PM CymaBay Publishes Shareholder LetterGlobeNewswire
Jan-15-20 07:25PM Edited Transcript of CBAY earnings conference call or presentation 5-Nov-19 9:30pm GMTThomson Reuters StreetEvents
02:01PM Edited Transcript of CBAY earnings conference call or presentation 5-Nov-19 9:30pm GMTThomson Reuters StreetEvents
Jan-10-20 02:21PM CymaBay Therapeutics Enters Oversold TerritoryZacks
Dec-31-19 04:48PM These Falling Knives May Be Worth CatchingGuruFocus.com
Dec-17-19 03:31PM Gilead (GILD) Announces Top-Line Results From NASH StudyZacks
Dec-10-19 08:36PM Genfit Hopes to Buck the Odds With NASH DrugGuruFocus.com
Dec-09-19 11:09AM Should You Take Comfort From Insider Transactions At CymaBay Therapeutics, Inc. (NASDAQ:CBAY)?Simply Wall St.
12:09AM Is CymaBay Therapeutics Inc (CBAY) Going To Burn These Hedge Funds ?Insider Monkey
Nov-29-19 04:24PM The Zacks Analyst Blog Highlights: Intercept, CymaBay, Amgen, Global Blood Therapeutics and ChemoCentryxZacks
01:41PM NASH Scorecard Year to Date: The Winners and the LosersZacks
Nov-27-19 03:09PM Biotech Stock Roundup: CBAY Falls, CCXI Gains, Amgen Acquires Otezla & MoreZacks
Nov-26-19 04:07PM Company News For Nov 26, 2019Zacks
01:24PM Intercept's (ICPT) NDA for NASH Drug Gets Priority ReviewZacks
Nov-26-19 01:06PM The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH DrugBenzinga
Nov-25-19 09:20PM This Biotech Popped After Its Rival Crashed 76% On A Scrapped TestInvestor's Business Daily
05:43PM This Biotech Flew To A 7-Month High On A Double Serving Of Good NewsInvestor's Business Daily
Nov-25-19 02:14PM UPDATE 2-CymaBay Therapeutics scraps two studies of liver drug; shares plungeReuters
01:34PM CymaBay shares fall 77% on halted trialMarketWatch
Nov-25-19 01:22PM CymaBay shares fall on halted trialMarketWatch
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis. The company also develops arhalofenate, which has completed five Phase II clinical trials for the treatment of patients with gout; and MBX-2982, an oral G-protein coupled receptor agonist that has completed one Phase II clinical trial for therapeutic indications. It has licensing agreement with Kowa Pharmaceuticals America, Inc. for the development and commercialization of arhalofenate in the United States; and Janssen Pharmaceuticals, Inc. to develop and discover undisclosed metabolic disease target agonists for the treatment of type II diabetes and other disorders, as well as a license and development agreement with DiaTex, Inc. to develop and commercialize therapeutic products comrprising halofenate and its enantiomers, derivatives, and analogs for the treatment of diseases. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.
Stocks in other countries: United Kingdom India Canada Australia
Market Cap
Volume (24h)